High-risk Myelodysplastic Syndrome
10
3
5
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (10)
A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
RVU120 Rollover Study
Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
The Patient Cohort of the National Center for Precision Medicine in Leukemia
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes
Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias